Scott Rivkees, M.D.
Academic Research Building, Room R1-118
- Postdoctoral, Harvard Medicial School, Neuroscience (1986 – 1989)
- Fellow, Massachusetts General Hospital/Harvard Medical School, Pediatric Endocrinology (1985 – 1989)
- Resident, Harvard Medical School/Massachusetts General Hospital, Pediatrics (1982 – 1985)
- M.D., New Jersey Medical School (1982)
Dr. Rivkees is a graduate of Rutgers University and the University of Medicine and Dentistry of New Jersey. He received postdoctoral training at Massachusetts General Hospital and Harvard Medical School, where he was also faculty. He authored more than 200 original articles, chapters, and editorials. He is the Editor-in-Chief of the International Journal of Pediatrics Endocrinology. He is a member of American Society for Clinical Investigation. He was the director of the multidisciplinary Yale Pediatric Thyroid Center. He started the Indiana Congenital Hypothyroidism Follow-up Program. At Yale, he was a member of the State Genetics Advisory Committee. He is a member of the American Thyroid Association Public Health Committee and is Chair of the Lawson Wilkins Pediatric Endocrine Society Public Policy Committee.
Dr. Rivkees developed a research program that is focused in three major areas: circadian biology, adenosinergic influences on brain injury of prematurity and the discovery of novel pediatric diagnostics and therapeutics. He discovered that the biological clock of preterm infants is responsive to low intensity lighting, leading to new treatment practices for preterm infants. He discovered that A1 adenosine receptor activation induces periventricular white matter injury (PWMI)-the most common neurological disorder affecting premature infants. He has recently discovered adverse effects on body composition and heart function related to prenatal caffeine exposure, findings reported widely in the press. Recently, he started a new research program aimed at the development of novel pediatric diagnostics and therapeutics. Most recently the Rivkees laboratory has begun to focus on the risks and adverse events associated with Graves’ disease therapy in children and during pregnancy.
- Developmental Endocrinology
- Thyroid Diseases
- Prevention of Brain Injury
- Circadian Biology
- Rivkees SA, Mattison, D, Ending Propylthiouracil (PTU)-induced Liver Failure in Children, New Eng J Medicine 2009 .9;360(15):1574-5.
- Wendler CC, Busovsky-McNeal M, Ghatpande S, Kalinowski A, Russell KS, Rivkees SA. Embryonic caffeine exposure induces adverse effects in adulthood. 2009 FASEB J. 2009;23(4):1272-8.
- Akundi RA, Rivkees SA. Hypoxia induces alteration of oligodendrocyte maturation and cell cycle regulation. PLoS ONE. 2009;4(3):e4739.
- Cooper DS, Rivkees SA. Putting Propylthiouracil in Perspective. J Clin Endocrinol Metab. 2009;94(6):1881-2.
- Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein IL, Laurberg P, McDougall R, Rivkees SA, Ross D, Sosa, J.A., Stan MN. The Role of Propylthiouracil (PTU) in the Management of Graves’ Disease in Adults: Report of a meeting jointly sponsored by the ATA and the FDA. Thyroid. 2009;19(7):673-4.